What are regulatory T cells (Treg) regulating in cancer and why?
What are regulatory T cells (Treg) regulating in cancer and why?
复制标题
DOI：
10.1016/j.semcancer.2012.03.004
复制
发表时间：
2012-08
影响因子：
14.5
通讯作者：
Whiteside TL
中科院分区：
文献类型：
--
作者：
Whiteside TL
调节性T细胞（Treg）在癌症发展和进展中的作用尚不清楚。早期证据表明，CD 4 + FOXP 3 + CD 25 high Treg在肿瘤和癌症患者外周血中聚集，并通过抑制抗肿瘤免疫反应促进肿瘤生长。然而，最近的数据表明，在某些癌症中，如结直肠癌（CRC），Treg抑制细菌驱动的炎症，促进致癌作用，从而使宿主受益。Treg似乎在癌症中发挥双重作用。这可能解释了为什么Treg的频率和功能与某些癌症的预后不良有关，但在其他癌症中却有良好的结果。Treg在癌症中的临床和预后意义取决于环境因素，包括感染因子、肿瘤衍生产物和局部产生的细胞因子，这些因素影响免疫应答的性质，包括Treg的产生、募集和存活。（i）Treg或Tr 1是癌症中存在的Treg的主要亚群。这些iTreg是调节细胞的独特子集，其在表型和功能上不同于负责外周耐受的F0 XP 3+天然（n）Treg。它们通过不同的机制介导效应T细胞的强大抑制，产生免疫抑制细胞因子，特别是TGF-β以及前列腺素E2和腺苷，并且对细胞凋亡或肿瘤治疗具有抗性。在癌症患者中沉默Tr 1的策略将需要新的方法，可以选择性地耗尽这些细胞或阻断它们利用的分子途径。
The role regulatory T cells (Treg) play in cancer development and progression is not clear. Earlier evidence suggested that CD4+FOXP3+CD25high Treg accumulate in tumors and the peripheral blood of patients with cancer and through suppression of anti-tumor immune responses promote tumor growth. However, more recent data indicate that in certain cancers, such as colorectal carcinoma (CRC), Treg suppress bacteria-driven inflammation which promotes carcinogenesis and thus benefit the host. Treg appear to play a dual role in cancer. This might explain why the frequency and functions of Treg are associated with a poor prognosis in some cancers but with favorable outcome in others. The clinical and prognostic significance of Treg in cancer depends on environmental factors, including infectious agents, tumor-derived products and locally-produced cytokines, which shape the nature of immune responses, including Treg generation, recruitment and survival. Adaptive or inducible (i) Treg or Tr1 are the major subset(s) of Treg present in cancer. These iTreg are a distinct subset of regulatory cells that phenotypically and functionally differ from FOXP3+ natural (n) Treg responsible for peripheral tolerance. They mediate powerful suppression of effector T cells via diverse mechanisms, produce immunosuppressive cytokines, notably TGF-β as well as prostaglandin E2 and adenosine, and are resistant to apoptosis or oncological therapies. Strategies for silencing of Tr1 in patients with cancer will require novel approaches that can selectively deplete these cells or block molecular pathways they utilize.
登录
查看更多内容
募集高危险性CD8（+）T细胞的潜在池募集到抗肿瘤免疫反应中。
DOI：
10.1084/jem.20042167
发表时间：
2005-05-16
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Ercolini AM;Ladle BH;Manning EA;Pfannenstiel LW;Armstrong TD;Machiels JP;Bieler JG;Emens LA;Reilly RT;Jaffee EM
通讯作者：
Jaffee EM
影响因子：
6.4
作者：
Erdman, Susan E.;Poutahidis, Theofilos
通讯作者：
Poutahidis, Theofilos
DOI：
10.1097/cji.0b013e3181d32f01
发表时间：
2010-05
期刊：
Journal of immunotherapy (Hagerstown, Md. : 1997)
影响因子：
--
作者：
Correale P;Rotundo MS;Del Vecchio MT;Remondo C;Migali C;Ginanneschi C;Tsang KY;Licchetta A;Mannucci S;Loiacono L;Tassone P;Francini G;Tagliaferri P
通讯作者：
Tagliaferri P
影响因子：
50.3
作者：
Bromberg J;Wang TC
通讯作者：
Wang TC
影响因子：
4.4
作者：
Clayton, Aled;Al-Taei, Saly;Tabi, Zsuzsanna
通讯作者：
Tabi, Zsuzsanna